(Q34992802)

5 August 2017

1 reference

title

Radiotherapy for cancer of the head and neck: altered fractionation regimens (English)

1 reference

Adaptive radiation therapy

5 August 2017

0 references

2

K Kian Ang

1 reference

5 August 2017

Linh N Nguyen

1

1 reference

5 August 2017

1 November 2002

1 reference

Lancet Oncology Commission

5 August 2017

1 reference

5 August 2017

3

1 reference

5 August 2017

11

1 reference

5 August 2017

693-701

1 reference

Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Dose fractionation, dose rate and iso-effect relationships for normal tissue responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Time-dose factors in radiotherapy: a review of the human data.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Dose response curves for organ function or cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Reduced oxygen enhancement ratio at low doses of ionizing radiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Onc

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900906-3

7 January 2021

10.1016/S1470-2045(02)00906-3

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12424072